Intellia Therapeutics Partners with Regeneron for Autoimmune Disease Therapy
Ticker: NTLA · Form: 8-K · Filed: Oct 25, 2024 · CIK: 1652130
Sentiment: neutral
Topics: collaboration, drug-development, autoimmune-disease
Related Tickers: REGN
TL;DR
Intellia teams up with Regeneron to fight autoimmune diseases with new gene therapy.
AI Summary
Intellia Therapeutics, Inc. announced on October 24, 2024, that it has entered into a clinical trial collaboration and supply agreement with Regeneron Pharmaceuticals, Inc. This agreement is for the development of a potential new therapy for autoimmune diseases. The collaboration will focus on advancing Intellia's allogeneic CAR T therapy, NTLA-5001, for the treatment of autoimmune diseases.
Why It Matters
This collaboration could accelerate the development of novel treatments for autoimmune diseases by combining Intellia's gene editing technology with Regeneron's expertise, potentially impacting millions of patients.
Risk Assessment
Risk Level: medium — The success of the collaboration and the therapy is subject to clinical trial outcomes and regulatory approvals, which carry inherent risks.
Key Players & Entities
- Intellia Therapeutics, Inc. (company) — Registrant
- Regeneron Pharmaceuticals, Inc. (company) — Collaboration Partner
- October 24, 2024 (date) — Date of earliest event reported
- NTLA-5001 (drug_candidate) — Allogeneic CAR T therapy for autoimmune diseases
FAQ
What is the primary focus of the collaboration between Intellia Therapeutics and Regeneron Pharmaceuticals?
The collaboration is focused on advancing Intellia's allogeneic CAR T therapy, NTLA-5001, for the treatment of autoimmune diseases.
What type of therapy is NTLA-5001?
NTLA-5001 is an allogeneic CAR T therapy.
What is the reported date of the earliest event in this 8-K filing?
The earliest event reported is dated October 24, 2024.
Which company is developing the allogeneic CAR T therapy being advanced in this collaboration?
Intellia Therapeutics is developing the allogeneic CAR T therapy, NTLA-5001.
What specific diseases is the collaboration aiming to treat?
The collaboration is aimed at treating autoimmune diseases.
Filing Stats: 1,346 words · 5 min read · ~4 pages · Grade level 14.5 · Accepted 2024-10-25 16:59:28
Key Financial Figures
- $0.0001 — ich registered Common Stock (Par Value $0.0001) NTLA The Nasdaq Global Market Ind
Filing Documents
- d842130d8k.htm (8-K) — 33KB
- d842130dex991.htm (EX-99.1) — 20KB
- g842130g14n45.jpg (GRAPHIC) — 5KB
- g842130g50s05.jpg (GRAPHIC) — 12KB
- 0001193125-24-244201.txt ( ) — 206KB
- ntla-20241024.xsd (EX-101.SCH) — 3KB
- ntla-20241024_lab.xml (EX-101.LAB) — 18KB
- ntla-20241024_pre.xml (EX-101.PRE) — 11KB
- d842130d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K and certain of the materials furnished or filed herewith contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia's beliefs and expectations regarding: the safety, efficacy, success and advancement of its clinical program for NTLA-2002 for the treatment of hereditary angioedema (HAE) pursuant to its clinical trial applications and investigational new drug application, including the potential for NTLA-2002 to become the first one-time treatment for HAE, the potential for NTLA-2002 to be a functional cure for people living with HAE and the potential of NTLA-2002 to redefine the treatment paradigm for HAE. Any forward-looking statements in this press release are based on management's current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to Intellia's ability to protect and maintain its intellectual property position; risks related to Intellia's relationship with third parties, including its licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; uncertainties related to the authorization, initiation, enrollment and conduct of studies and other development requirements
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release dated October 24, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Intellia Therapeutics, Inc. Date: October 25, 2024 By: /s/ John M. Leonard Name: John M. Leonard Title: Chief Executive Officer and President